Evidence map›Paper›PMID 38098602›Full record

ReviewAnnals of medicine and surgery (2012)2023

Drug delivery methods based on nanotechnology for the treatment of eye diseases.

Mohammed Tayeb Oucif Khaled, Abdelmalekd Zaater, Ilham Ben Amor, Soumeia Zeghoud, Asma Ben Amor, Hadia Hemmami, Ali Alnazza Alhamad

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of medicine and surgery (2012), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Mohammed Tayeb Oucif KhaledDepartment of Process Engineering and Petrochemical, Faculty of Technology, University of El Oued, El Oued, Algeria.
Abdelmalekd ZaaterDepartment of Agronomy, Faculty of Nature and Life Sciences, University of El Oued, El Oued, Algeria.
Ilham Ben AmorDepartment of Process Engineering and Petrochemical, Faculty of Technology, University of El Oued, El Oued, Algeria.
Soumeia ZeghoudDepartment of Process Engineering and Petrochemical, Faculty of Technology, University of El Oued, El Oued, Algeria.
Asma Ben AmorDepartment of Process Engineering and Petrochemical, Faculty of Technology, University of El Oued, El Oued, Algeria.
Hadia HemmamiDepartment of Process Engineering and Petrochemical, Faculty of Technology, University of El Oued, El Oued, Algeria.
Ali Alnazza AlhamadDepartment of Chemistry, Faculty of Science, University of Aleppo, Aleppo, Syrian Arab Republic.
Centre Hospitalo-Universitaire Bab El Oued · DZUniversity of Aleppo · SYUniversity of Eloued · DZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the most difficult tasks among the numerous medication delivery methods is ocular drug delivery. Despite having effective medications for treating ocular illness, we have not yet managed to develop an appropriate drug delivery strategy with the fewest side effects. Nanotechnology has the potential to significantly address the drawbacks of current ocular delivery systems, such as their insufficient therapeutic effectiveness and unfavourable side effects from invasive surgery or systemic exposure. The objective of the current research is to highlight and update the most recent developments in nano-based technologies for the detection and treatment of ocular diseases. Even if more work has to be done, the advancements shown here might lead to brand-new, very practical ocular nanomedicines.

Indexed as

drug delivery systemsnanocarriersnanotechnologyocular barriersocular diseasestreatment

Identifiers

PMID38098602
PMCPMC10718325
OpenAlexW4387701605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.